テルイ　ヤスヒト   TERUI Yasuhito   照井　康仁    所属   埼玉医科大学  医学部 血液内科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia
掲載誌名	正式名：Cancer Sci ISSNコード：13497006
掲載区分	国外
巻・号・頁	111,3327-3337頁
著者・共著者	Sekiguchi, N., Rai, S., Munakata, W., Suzuki, K., Handa, H., Shibayama, H., Endo, T., Terui, Y., Iwaki, N., Fukuhara, N., Tatetsu, H., Iida, S., Ishikawa, T., Shiibashi, R., Izutsu, K.
発行年月	2020
概要	Tirabrutinib is a second-generation Bruton's tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment-naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström's macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall response rate (ORR; ≥ minor response), time to major response (TTMR), progression-free survival (PFS), overall survival (OS), and safety. In total, 27 patients (18 in Cohort A; 9 in Cohort B) were enrolled. The median age was 71 y, and the median serum immunoglobulin M level was 3600 mg/dL. Among the patients, 96.2% had the MYD88
DOI	10.1111/cas.14561
文献番号	32639651